Genetron Health to Participate at Credit Suisse Asian Investment Conference on Mar. 26th, 2021
Genetron Holdings Limited (Nasdaq: GTH), a prominent precision oncology platform in China, has announced management's participation in virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on March 26, 2021. CEO Sizhen Wang will also engage in a fireside chat at 3:00 PM Beijing time. Genetron Health specializes in molecular profiling tests, cancer screening products, and companion diagnostics, leveraging advanced technologies to enhance cancer treatment and management. Interested parties can obtain further details by contacting Credit Suisse sales representatives.
- None.
- None.
Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will host virtual investor meetings at the 24th Credit Suisse Asian Investment Conference on Mar. 26th, 2021.
Sizhen Wang, co-founder and Chief Executive Officer, will also attend a fireside chat at 3:00 pm Beijing time (3:00 am ET).
Interested parties may request more information by contacting their sales representative at Credit Suisse.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005790/en/
FAQ
What event is Genetron Holdings Limited participating in on March 26, 2021?
Who will represent Genetron at the Credit Suisse Asian Investment Conference?
What is the focus of Genetron Holdings Limited?
Where can I find more information about Genetron Holdings Limited?
What is the stock symbol for Genetron Holdings Limited?
